| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3214945 | F | PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation. (Class of assay: confirmatory) | 940 | assay format | PubChem BioAssays | |||
| 2. | ALA3215001 | F | PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation. (Class of assay: confirmatory) | 1,150 | assay format | PubChem BioAssays | |||
| 3. | ALA3214813 | F | PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2). (Class of assay: confirmatory) | 1,069 | assay format | PubChem BioAssays | |||
| 4. | ALA3214842 | F | PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation. (Class of assay: confirmatory) | 881 | assay format | PubChem BioAssays | |||
| 5. | ALA4296184 | F | Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) | Staphylococcus aureus | 4,588 | organism-based format | CO-ADD antimicrobial screening data | ||
| 6. | ALA4296185 | F | Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) | Escherichia coli | 4,585 | organism-based format | CO-ADD antimicrobial screening data | ||
| 7. | ALA4296186 | F | Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) | Klebsiella pneumoniae | 6,160 | organism-based format | CO-ADD antimicrobial screening data | ||
| 8. | ALA4296187 | F | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) | Pseudomonas aeruginosa | 24,161 | organism-based format | CO-ADD antimicrobial screening data | ||
| 9. | ALA4296188 | F | Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 | Acinetobacter baumannii | 22,588 | organism-based format | CO-ADD antimicrobial screening data | ||
| 10. | ALA4296189 | F | Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 | Candida albicans | 6,134 | organism-based format | CO-ADD antimicrobial screening data | ||
| 11. | ALA4296190 | F | Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) | Cryptococcus neoformans | 6,133 | organism-based format | CO-ADD antimicrobial screening data | ||
| 12. | ALA5303574 | A | The drug is tested on Bifidobacterium adolescentis strain: ATCC 15703 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium adolescentis | 247 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 13. | ALA5303575 | A | The drug is tested on Bifidobacterium breve strain: DSM20213 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium breve | 225 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 14. | ALA5303576 | A | The drug is tested on Bifidobacterium longum subsp. Infantis strain: CCUG52486 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium longum subsp. Infantis | 243 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 15. | ALA5303577 | A | The drug is tested on Bifidobacterium ruminantium strain: fecal isolate for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bifidobacterium ruminantium | 208 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 16. | ALA5303578 | A | The drug is tested on Collinsella aerofaciens strain: ATCC25986 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Collinsella aerofaciens | 258 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 17. | ALA5303579 | A | The drug is tested on Collinsella intestinalis strain: DSM13280 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Collinsella intestinalis | 254 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 18. | ALA5303580 | A | The drug is tested on Eggerthella lenta strain: ATCC25559 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Eggerthella lenta | 152 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 19. | ALA5303581 | A | The drug is tested on Alistipes indistinctus strain: DSM22520 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Alistipes indistinctus | 202 | assay format | Zimmerman Lab Biotransformation data Dec 2023 | ||
| 20. | ALA5303582 | A | The drug is tested on Bacteroides caccae strain: ATCC43185 for biotransformation. The drug concentrations were measured before and after a 12-h incubation by liquid-chromatography-coupled mass spectrometry (LC–MS) | Bacteroides caccae | 239 | assay format | Zimmerman Lab Biotransformation data Dec 2023 |
The page will load shortly, Thanks for your patience!